Antibodies directed to the mammalian EAG1 ion channel protein

Details Antibodies directed to the mammalian EAG1 ion channel protein Antibodies directed to the mammalian EAG1 ion channel protein

2011-03-22

2011-03-22

Kemmerer, Elizabeth C. (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S135100, C424S136100, C424S139100, C424S156100, C424S009341, C435S007100, C435S007230, C530S387900, C530S387300, C530S388150

Reexamination Certificate

active

07910100

ABSTRACT:
The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain or the mammalian EAG1 ion channel and to nucleic acid molecules encoding these anti-EAG1 antibodies, antibody fragments or derivatives and to vectors comprising such nucleic acid molecules. The invention additionally relates to methods for the preparation of such anti-EAG1 antibodies, antibody fragments or derivatives thereof, pharmaceutical compositions comprising these antibodies, antibody fragments or derivatives, and methods of using the antibodies, antibody fragments or derivatives or the compositions for a variety of purposes, such as diagnosing disease, treating disease, assessing for the presence of EAG1-expressing cells, or blocking EAG1 function in cells.

REFERENCES:
patent: 5741957 (1998-04-01), Deboer
patent: 5750172 (1998-05-01), Meade et al.
patent: 5756687 (1998-05-01), Denman et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5877293 (1999-03-01), Adair et al.
patent: 5886152 (1999-03-01), Nakatani
patent: 6054297 (2000-04-01), Carter et al.
patent: 2004/0254108 (2004-12-01), Ma et al.
patent: 0239400 (1994-08-01), None
patent: 1073738 (2004-09-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 98/09622 (1998-03-01), None
patent: WO 00/09560 (2000-02-01), None
Padlan EA et al. Structure of an antibody-antigen complex: Crystal structure of the HyHEL-10 Fab-lysozyme complex. Proc Natl Acad Sci USA, 1989; 86:5938-5942.
Paul WE, Fundamental Immunology, Third Edition. Raven Press, New York, 1993, pp. 292-295.
H. Ouadid et al., “Changes in the K+ Current-Density of MCF-7 Cells During Progression Through the Cell Cycle: Possible Involvement of a h-ether.a-gogo K+ Channel”Receptors Channels., 7:345-56, (2001).
R. Meyer et al., “Identification of Ether a Go-Go and Calcium-Activated Potassium Channels in Human Melanoma Cells.”,J Membr Biol., 171:107-15, (1999).
L. Bianchi et al., “herg encodes a K+Current Highly Conserved in Tumors of Different Histogenesis: A Selective Advantage for Cancer Cells?1”,Cancer Res. 58:815-22, (1998).
Davies et al., “Affinity improvement of single antibody VH domains: residues of all three hypervariable regions affect antigen binding,”Immunotechnology, 2(3):169-179 (1996).
Holt et al., “Domain antibodies: proteins for therapy,”Trends in Biotechnology, 21(11):484-490 (2003).
G. Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity.”,Nature., 256(5517):495-7, (1975).
R. Schier et al., “Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections.”Hum Antibodies Hybridomas, 7(3):97-105, (1996).
A. Malmborg et al., “BIAcore as a tool in antibody engineering.”,J Immunol Methods, 183:7-13, (1995).
H. Le Mouellic et al., “Targeted replacement of the homeobox geneHox-3.1by theEscherichia coli lacZin mouse chimeric embryos.”,Proc Natl Acad Sci U S A., 87:4712-16, (1990).
R. Mandler et al., “Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines.”,J Natl Cancer Inst., 92(19):1573-81, (2000).
S. Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy.”,Nat Biotechnol, 21 (7):778-784, (2003).
C. Chothia et al. “Domain Association in Immunoglobulin Molecules The Packing of Variable Domains”,J. Mol, Biol., 186:651-63, (1985).

Affiliated with

Also associated with

Rating

Antibodies directed to the mammalian EAG1 ion channel protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies directed to the mammalian EAG1 ion channel protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies directed to the mammalian EAG1 ion channel protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2717053